Literature DB >> 19362888

Maximizing the Alzheimer's Disease Neuroimaging Initiative II.

Maria C Carrillo1, Charles A Sanders, Russell G Katz.   

Abstract

The Alzheimer's Disease Neuroimaging Initiative is the largest public-private partnership on brain research underway at the National Institutes of Health. This 6-year study tracks cognitive and brain changes in normal subjects, those with mild cognitive impairment, and individuals with Alzheimer's disease. It was designed to provide better tools for performing effective clinical trials, and is slated to run until 2010. While data are being generated and analyzed, researchers involved in the study are developing an extension, i.e., the Alzheimer's Disease Neuroimaging Initiative II. The Foundation for the National Institutes of Health and the Alzheimer's Association convened a meeting to review the progress, evaluate future directions, and obtain the United States Food and Drug Administration's perspective on how the Alzheimer's Disease Neuroimaging Initiative could affect the drug-approval process.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19362888     DOI: 10.1016/j.jalz.2009.02.005

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  9 in total

Review 1.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

Review 2.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-06       Impact factor: 21.566

Review 3.  Power calculations for clinical trials in Alzheimer's disease.

Authors:  M Colin Ard; Steven D Edland
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): a completed reference database of lung nodules on CT scans.

Authors:  Samuel G Armato; Geoffrey McLennan; Luc Bidaut; Michael F McNitt-Gray; Charles R Meyer; Anthony P Reeves; Binsheng Zhao; Denise R Aberle; Claudia I Henschke; Eric A Hoffman; Ella A Kazerooni; Heber MacMahon; Edwin J R Van Beeke; David Yankelevitz; Alberto M Biancardi; Peyton H Bland; Matthew S Brown; Roger M Engelmann; Gary E Laderach; Daniel Max; Richard C Pais; David P Y Qing; Rachael Y Roberts; Amanda R Smith; Adam Starkey; Poonam Batrah; Philip Caligiuri; Ali Farooqi; Gregory W Gladish; C Matilda Jude; Reginald F Munden; Iva Petkovska; Leslie E Quint; Lawrence H Schwartz; Baskaran Sundaram; Lori E Dodd; Charles Fenimore; David Gur; Nicholas Petrick; John Freymann; Justin Kirby; Brian Hughes; Alessi Vande Casteele; Sangeeta Gupte; Maha Sallamm; Michael D Heath; Michael H Kuhn; Ekta Dharaiya; Richard Burns; David S Fryd; Marcos Salganicoff; Vikram Anand; Uri Shreter; Stephen Vastagh; Barbara Y Croft
Journal:  Med Phys       Date:  2011-02       Impact factor: 4.071

Review 5.  Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

Authors:  Harald Hampel; Kaj Blennow; Leslie M Shaw; Yvonne C Hoessler; Henrik Zetterberg; John Q Trojanowski
Journal:  Exp Gerontol       Date:  2009-10-22       Impact factor: 4.032

Review 6.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Li Shen; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2013-08-07       Impact factor: 21.566

Review 7.  Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact.

Authors:  Remco L A de Vrueh; Daan J A Crommelin
Journal:  Pharm Res       Date:  2017-06-06       Impact factor: 4.200

Review 8.  Alzheimer's disease: An alternative approach.

Authors:  Sadanandavalli Retnaswami Chandra
Journal:  Indian J Med Res       Date:  2017-06       Impact factor: 2.375

9.  Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities.

Authors:  Francesca Pistollato; Elan L Ohayon; Ann Lam; Gillian R Langley; Thomas J Novak; David Pamies; George Perry; Eugenia Trushina; Robin S B Williams; Alex E Roher; Thomas Hartung; Stevan Harnad; Neal Barnard; Martha Clare Morris; Mei-Chun Lai; Ryan Merkley; P Charukeshi Chandrasekera
Journal:  Oncotarget       Date:  2016-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.